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Abstract
Background: Recently, long-acting injection (LAI) of second-generation antipsychotics has become a valuable strategy
for the treatment of schizophrenia. However, few studies have compared the effects of different LAI antipsychotics on
cognitive functions so far. The present study aimed to compare the influence of risperidone LAIs (RLAI) and paliperidone
palmitate LAIs (PP) on cognitive function in outpatients with schizophrenia.
Methods: In this 6-month, open-label, randomized, and controlled study, 30 patients with schizophrenia who were
treated with RLAIs were randomly allocated to the RLAI-continued group or the PP group. At baseline and 6 months,
the patients were evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) that was the primary
outcome of the study. The Subjective Well-being under Neuroleptic drug treatment-Short form (SWNS), the Positive
and Negative Syndrome Scale (PANSS), and the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) scores were
secondary outcome variables and they were tested at the same time points.
Results: The two groups did not differ in terms of PANSS, DIEPSS, or SWNS total score changes. However, the
BACS score for the attention and processing speed item showed higher improvement in the PP group than
the RLAI group (p = 0.039).
Conclusions: The results of this preliminary study suggest that PPs may improve attention and processing speed
more than RLAIs. Anyway, a replication in a larger and double-blind study is needed.
Trial registration: UMIN000014470. Registered 10 July 2014
Keywords: Schizophrenia, Risperidone long-acting injection, Paliperidone palmitate, Cognitive function, Efficacy,
Subjective well-being
Background
Schizophrenia is a devastating disease that has a chronic
or intermittent course with numerous relapses over time
[1]. Relapses of schizophrenia are known to adversely
affect many biological functions [2] and antipsychotic
treatment is pivotal for preventing relapses [3]. Anyway, in
clinical setting patients’ compliance to oral antipsychotics
is often poor and difficult to maintain over time [4], result-
ing in a heavy impact on the risk of relapse [5].
Previous studies reported that several factors are
related to the adherence to antipsychotic drugs, many of
them are patient-related factors (e.g. symptom severity,
illness insight, attitude to medication or subjective well-
being), but there are also medication-related factors (e.g.
side effects), and environment-related factors (e.g. thera-
peutic alliance) [6–9]. One possible approach to manage
patient non-adherence is the use of long-acting injec-
tions (LAI) [10]. Many studies have reported remarkable
improvements in psychiatric symptoms and/or a higher
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efficacy in preventing recurrence/relapse when patients
with schizophrenia are treated with LAIs [11].
Among the second-generation antipsychotics (SGAs),
the present study examined risperidone (RIS) LAIs
(RLAI) and paliperidone (PAL) palmitate LAIs (PP) that
was recently marketed in many countries. PP is an active
metabolite of RIS, and they resemble each other in many
aspects. However, they differ in some of their pharmaco-
logical features [12]. Indeed, previous clinical studies
compared Oral-RIS and Oral-PAL and they reported
some differences pertaining the effects on cognitive
functions [13, 14]. The treatment of neurocognitive defi-
cits is another key target of treatment [15], since deficits
in neurocognitive functions are among the core symp-
toms of schizophrenia [16]. Although some trials investi-
gating cognitive functions in patients treated with RLAI
were performed, PP was never investigated in relation to
that issue [17, 18]. No study directly comparing RLAI
and PP was performed so far, neither comparing their ef-
fects on cognitive functions.
Accordingly, the present paper aims to compare the
influence of RLAIs and PPs on cognitive functions using
the Brief Assessment of Cognition in Schizophrenia
(BACS) score as the primary outcome. As secondary
outcomes, we investigated the differences between the
drugs on measures of psychiatric symptoms, extrapyr-
amidal symptoms, and subjective well-being, which are
relevant issues in regard to long-term LAI use and
adherence to antipsychotics.
Methods
Study design and setting
This was a 24-week pilot study using an open-label, par-
allel, randomized controlled design. It was conducted at
Kansai Medical University Takii Hospital in Osaka from
July 2014 to February 2015, in accordance with the
Declaration of Helsinki. The trial protocol was approved
by the institutional review board at Kansai Medical
University. After a full description of the study, all par-
ticipants provided written informed consent prior to
entering the study. We described this clinical trial ac-
cording to the CONSORT 2010 guidelines. Enrollment,
allocation, and follow-up of the study patients are
depicted in the CONSORT diagram (Fig. 1). A support-
ing CONSORT 2010 checklist is available as supplemen-
tary information (see Additional file 1).
Patients
All patients were at least 20 years old and had been diag-
nosed with schizophrenia or schizoaffective disorder based
on the DSM-IV-TR criteria. The inclusion criteria were: 1)
being during a non-acute phase of disease; 2) Positive and
Negative Syndrome Scale (PANSS) total score of 120 or
less; and 3) having received RLAI for 2 months or longer.
The exclusion criteria were; 1) comorbid serious physical
disorder; 2) active suicidal ideation; 3) history of attempted
suicide; 4) history of drug or alcohol abuse; 5) mental re-
tardation; 6) pregnancy; 7) current treatment with Oral-
RIS, Oral-PAL; or 8) current treatment with multiple oral
antipsychotics. Intelligence quotient was assessed using
the Japanese Adult Reading Test (JART) [19]. For the dur-
ation of the study, subjects were allowed to take anti-
cholinergic agents for new extrapyramidal symptoms,
drugs for concomitant medical conditions if they started
taking them before the enrollment in the study, low-dose
sleep-inducing medications as needed, and other drugs
considered to have no effect on the outcomes of interest.
Additional administration of new antipsychotics, except
for RLAI and PP, was not allowed during the study.
Fig. 1 CONSORT flow of participants through the trial
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Procedures
Patients satisfying the inclusion criteria were randomized
1:1 to either the RLAI-continued group (hereafter, the
RLAI group) or the PP group using the random number
generation program of the SPSS software, version 21
(IBM SPSS, Tokyo, Japan). Patients in the RLAI group
continued their treatment with the same dose of RLAI,
and then underwent intramuscular injection into the
gluteal muscles every 2 weeks. The dose was determined
depending on each patient’s clinical status, with an
upper limit of 50 mg/2 weeks. Patients in the PP group
started the treatment by intramuscular injection into the
deltoid or gluteal muscles. Their starting dose was
equivalent to twice the dose of RLAI [20]. In the present
study, a 4-week PP preparation was used. The dose was
determined depending on each patient’s clinical status,
with an upper limit of 150 mg/4 weeks.
Outcome measures
The primary outcome was the baseline-6 month change
in BACS score between the RLAI group and the PP
group. The secondary outcomes were the baseline-
6 month changes in subjective well-being, psychiatric
symptoms, and extrapyramidal symptoms between the
two groups. Finally, the correlation between the changes
in cognitive function and the changes in subjective well-
being were evaluated.
The following assessments were performed at baseline
and after 24 weeks: the BACS, Japanese version for cogni-
tive function [16]; the Subjective Well-being under Neuro-
leptic drug treatment Short form (SWNS) [21, 22],
Japanese version for subjective well-being; PANSS for clin-
ical psychopathology [23]; and the Drug-Induced Extra-
pyramidal Symptoms Scale (DIEPSS) for extrapyramidal
symptoms [24].
The BACS is a tool for measuring cognitive function
in patients with schizophrenia that consists of six items:
verbal memory, working memory, motor speed, verbal
fluency, attention, processing speed, and executive func-
tion [25]. Sufficient reliability and validity have been
established for the BACS Japanese version [16]. In ac-
cordance with several previous studies using the BACS,
the primary outcome measures were standardized into
z-scores (the mean of healthy controls was set to zero,
and the standard deviation was set to one) [25–27]. In
the present study, the data for healthy controls were ob-
tained from a previous study [28]. The BACS score was
adjusted for age using age-matched controls to calculate
the BACS-J z-scores for each schizophrenia patient in
the present study.
The SWNS is a tool for measuring subjective well-
being in patients with schizophrenia undergoing anti-
psychotic treatment. It consists of 20 questions covering
five categories: mental function, self-control, emotional
regulation, physical functioning, and social integration.
Sufficient reliability and validity have been established
for the SWNS Japanese version [29]. Each question is
answered using a 6-point scale, with higher scores indi-
cating higher subjective well-being.
Due to the open-label design of the study, neither pa-
tients nor raters were blind to patients’ group assignment.
Statistical analysis
The analysis was performed only for patients who com-
pleted all the 24 weeks of the study. The raw data col-
lected at baseline and endpoint were used for the analysis.
To ensure group comparability, baseline clinical charac-
teristics were tested by t-tests or Pearson’s chi-square tests
as appropriate. Analysis of covariance (ANCOVA) was
used to assess the change of BACS z-scores, SWNS
scores, PANSS scores, DIEPSS, and antipsychotic dose in
each treatment group using the baseline score as covari-
ate. Only in the analysis of BACS z-score change the anti-
psychotic dose was used as covariate in addition to the
baseline score because a significant correlation was ob-
served between the BACS z-score and the antipsychotic
dose. An exploratory Pearson’s correlational analysis was
used to determine potential associations between changes
in cognitive and subjective well-being scores. Analyses
were performed with SPSS software, version 21.0 J (SPSS,
Tokyo, Japan). All statistical tests were two-tailed, and a
p-value less than 0.05 was considered significant.
Results
Demographic and clinical characteristics
Thirty patients were allocated into the two groups (RLAI
group, n = 16; PP group, n = 14) at the start of the study.
During the study, 5 patients from the RLAI group and 4
from the PP group dropped out of the study (Fig. 1).
Thus, the final analysis included the 21 patients who
completed the study (11 in the RLAI group and 10 in
the PP group). The clinical-demographic characteristics
of the sample are shown in Table 1. At baseline, the two
groups did not differ significantly in age, onset, sex,
diagnosis, PANSS total score, DIEPSS total score (sum
of scores for items 1 to 8), total antipsychotics dose
(chlorpromazine equivalent), or concomitant medica-
tions. Concomitant medications that a patient have
started before the inclusion in the study were allowed to
continue until the end of the study. During the 24-week
study period, two patients from the PP group were also
treated with low-dose ultrashort-acting hypnotics for
new insomnia, and one patient from the same group was
treated with an anti-hyperlipidemia drug for new hyper-
lipidemia. The patients were not treated with other
drugs, including psychotropics.
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Cognitive function
At baseline, the RLAI and PP groups did not differ in
any of the BACS z-scores. In the analysis of the changes
in the BACS z-scores from baseline to the study end-
point, the attention and processing speed score showed
higher improvement in the PP group compared to the
RLAI group (p = .039; partial eta-squared = .228;
95%CI = −.79 to -.02; Table 2). There were no signifi-
cant intergroup differences in the changes in the other
scores, including the total score of each scale.
Subjective well-being
No statistically significant differences were found for the
all of baseline SWNS items score between the two groups.
In the analysis of the changes in the SWNS scores from
baseline to the endpoint, the emotional regulation score
showed higher improvement in the PP group compared to
the RLAI group (p = .034; partial eta-squared = .238;
95%CI = −5.90 to -.26; Table 3). There were no significant
intergroup differences in the total score or in the changes
in any of the other scores.
Changes in PANSS scores, DIEPSS total scores and dose of
antipsychotic drugs
There were no significant differences in PANSS score,
DIEPSS total score, or antipsychotic doses at baseline
between the two groups. In addition, the changes in
these scores from the baseline to endpoint did not differ
between the two groups (Table 3).
Associations between changes in BACS scores and
changes in SWNS scores
The changes in the SWNS total score did not correlate
with the changes in any of the BACS z-scores. However,
a correlation was found between improvements in the
BACS score of attention and processing speed and the
SWNS subscale of emotional regulation (r = .46, p = .037;
Table 4). There were no significant correlations between
any of the other BACS scores and any of the other sub-
scales of the SWNS.
Discussion
To the best of our knowledge, the present randomized
study is the first attempt to evaluate changes in cognitive
function in patients with schizophrenia during RLAI or
PP treatment. The most clinically relevant finding ob-
tained by this preliminary study is that patients who
switch from RLAI to PP might have higher improvement
in attention and processing speed than those who con-
tinue treatment with RLAL. Although the differences in
effects on cognitive function observed between the two
groups were very small, our results might have some im-
plications for the treatment of schizophrenia.
To date, a number of studies have investigated the in-
fluence of pharmacological therapy on cognitive function
in patients with schizophrenia. Many reports have dem-
onstrated a slightly to moderately favorable influence of
Table 1 Demographic and Clinical Characteristics of Patients
RLAI group PP group p
Age (years) 46.4 ± 10.4 43.5 ± 11.8 NS
Onset (years) 29.5 ± 11.9 32.9 ± 11.7 NS
Sex (Male/Female) 7/4 4/6 NS
Diagnosis (schizophrenia/schizoaffective
disorder)
11/0 9/1 NS
PANSS total score 83.0 ± 19.9 78.1 ± 21.0 NS
DIEPSS total score 3.1 ± 3.1 1.1 ± 1.7 NS
Total antipsychotics dosea 432 ± 112.6 342 ± 94.7 NS
Residence status (solitude/not solitude) 4/7 3/7 NS
Concomitant medication, n (%)
Anticholinergic drugs 1 (9) 0 (0) NS
NS no significant difference, RLAI risperidone long-acting injection, PP paliperidone
palmitate, PANSS the positive and negative syndrome scale, DIEPSS the drug-
induced extrapyramidal symptoms scale
aChlorpromazine-equivalent dose
Table 2 Change of primary outcome measures in risperidone long acting injection and paliperidone palmitate groups
RLAI group PP group Difference in change between groups
Baseline Change Baseline Change p Partial eta-squared 95%CI
Mean SD Mean SD Mean SD Mean SD
BACS
Verbal learning 6 1.04 .23 1.59 −1.34 .94 .06 1.22 .597 .017 −1.88 to 1.10
Working memory −2.12 1.15 .12 .77 −1.10 .91 .26 .62 .412 .040 −1.09 to .470
Motor function −2.65 .75 .28 .99 −2.74 1.09 .80 1.31 .374 .047 −1.80 to .71
Verbal fluency −1.60 .83 .12 .50 −1.35 .97 .48 .60 .174 .106 −.93 to .18
Attention and processing speed −2.65 1.37 .32 .36 −1.69 1.33 .62 .36 .039* .228 −.79 to -.02
Executive function −2.03 2.80 .63 2.69 −.44 1.09 −.13 .99 .171 .107 −1.76 to .34
Composite score −2.22 .95 .29 .49 −1.44 .58 .35 .52 .290 .066 −.80 to .25
*p < .05
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antipsychotic treatment on the cognitive function of pa-
tients with schizophrenia [30]. However, some studies have
reported that cognitive function is negatively affected by
standard- and high-dose antipsychotic treatment [31–34],
antipsychotic polypharmacy [27], concomitant use of anti-
Parkinson’s disease drugs [35], or concomitant use of ben-
zodiazepines [36]. Thus, particular attention to drug doses
and combinations is the first measure to avoid cognitive
dysfunction. As a further step, the effects of different anti-
psychotics on cognitive function have been examined by
several studies. Differences between the impact of SGAs
and first-generation antipsychotics (FGAs) on cognition
have frequently been reported [37]. However, studies
focused on the possible different effects of different
SGAs found both negative [38, 39] and positive re-
sults [13, 40, 41]. Given that individual SGAs show
different pharmacological profiles and that cognitive
function consists of diverse domains, it seems likely
that the effects on cognitive function may differ (even
if slightly) among drugs [42].
Regarding the present study, the different pharmacoki-
netic and pharmacodynamic properties between RLAIs
and PPs should be considered. The greatest pharmacoki-
netic difference between the two compounds pertains to
the PAL/RIS drug level ratio in the blood. PP works
exactly as PAL, while the PAL/RIS blood ratio during
RLAI treatment (both 25, 37.5, and 50 mg/14 days) was
reported to be 2.4–3.0 [43] and much higher during
Oral-RIS treatment (2 mg/day: 13.3, 4 mg/day: 11.5,
6 mg/day: 13.3). One possible reason for such a low
PAL/RIS for RLAI is the lack of a first pass effect in the
liver. This suggests that RLAI is a drug that more
strongly reflects the influence of RIS compared to PP
and Oral-RIS.
Under the pharmacodynamic point of view, PAL and
RIS show many similarities in their affinities for recep-
tors. However, their affinities for the alpha 2-adrenergic
receptor are different, since PAL has a higher affinity
than RIS for this receptor [12]. Animal studies have
shown that the blockage of alpha 2-adrenergic receptors
greatly affects the release of dopamine and noradren-
aline from the medial prefrontal cortex [44]. Clinical
Table 3 Change of secondary outcome measures in risperidone long acting injection and paliperidone palmitate groups
RLAI group PP group Difference in change between groups
Baseline Change Baseline Change p Partial eta-squared 95%CI
Mean SD Mean SD Mean SD Mean SD
SWNS
Total score 79.09 19.93 −.09 19.58 67.00 19.25 3.20 7.36 .655 .012 −9.07 to 14.06
Mental function 16.00 4.52 −.18 4.58 12.60 3.92 .70 3.02 .990 < .001 −3.74 to 3.69
Self-control 15.45 4.44 1.46 5.18 14.20 3.49 .40 3.13 .267 .072 −1.91 to 6.48
Emotional regulation 16.55 4.06 −1.91 3.73 13.20 3.77 1.80 1.93 .034* .238 −5.90 to -.26
Physical functioning 15.64 5.32 −1.27 5.95 13.80 4.54 .30 2.50 .825 .003 −4.89 to 3.951
Social integration 15.36 5.63 −.36 4.37 13.40 4.86 .00 2.16 .492 .028 −1.69 to 3.38
PANSS
Total 83.00 19.88 −5.09 8.18 78.10 21.02 −1.70 5.08 .349 .049 −8.90 to 3.31
Positive 18.64 5.32 −2.00 2.65 16.30 4.72 −.30 2.00 .222 .082 −3.39 to .84
Negative 21.73 5.14 −.73 1.10 20.10 6.06 .20 1.62 .136 .119 −2.27 to .34
General psychopathology 42.64 10.88 −2.36 5.45 41.70 11.05 −1.60 2.50 .732 .007 −4.39 to 3.14
DIEPSS total 2.55 2.60 −.09 .30 0.90 1.28 .30 1.06 .220 .082 −1.23 to .30
Total antipsychotic dosea 432 112.6 −12.6 18.6 342 94.7 −26.8 52.0 .651 .012 −30.41 to 47.43
aChlorpromazine-equivalent dose, *p < .05
Table 4 Correlations between changes in BACS scores and
changes in SWNS scores
BACS
VL WM MoF VF AP EF COM
SWNS TS −.03 −.05 .03 −.24 .29 .17 .08
MeF −.07 .13 .05 −.19 .24 .33 .21
SC −.28 .01 .02 −.27 .06 .16 −.08
ER .11 −.15 .23 .09 .46* −.03 .20
PF −.13 .03 .14 −.20 .09 .26 .14
SI .08 −.05 .03 -.13 .23 .33 .24
BACS brief assessment of cognition in schizophrenia, SWNS subjective well-
being under neuroleptic drug treatment short form, VL verbal learning, WM
working memory, MF motor function, VF verbal fluency, AP attention and
processing speed, EF executive function, COM composite score, TS total score,
MF mental function, SC self-control, ER emotional regulation, PF physical
functioning, SI social integration
*p < .05
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studies have demonstrated that treatment with antide-
pressants with strong alpha 2-adrenergic receptor antag-
onistic activity (e.g. mirtazapine [45] or mianserin [46])
may improve cognitive function. Furthermore, many stud-
ies in humans, monkeys, and rodents have demonstrated
that the noradrenergic nervous system, particularly
through the alpha 2-adrenergic receptor, contributes to
the regulation of attention [47]. Given that attention is a
markedly disturbed cognitive domain in schizophrenia,
the results of the present study deserve to be investigated
by future studies. The results of a previous study [13] that
compared Oral-RIS and Oral-PAL are poorly comparable
with the present ones, since the reported pharmacokinetic
differences among RLAIs, PPs, Oral-RIS, and Oral-PAL.
In addition to these differences, the following issues
should be considered: (1) the range of fluctuations in
blood levels of Oral-RIS and Oral-PAL differ substantially
(peak-to-trough fluctuation: 1.47 for Oral-PAL, 3.30 for
Oral-RIS) [48]; (2) the frequency of sedation is higher with
Oral-RIS than with Oral-PAL [49]; and (3) Oral-RIS may
adversely affect working memory, a cognitive functional
domain related to short-term memory [50].
In the present study, there were no differences be-
tween the two groups in the change in the total scores
of the PANSS and DIEPSS. These results suggest similar
efficacy and tolerability of RLAI and PP, consistently
with previous studies [51–53].
The total score of the SWNS did not differ between
the two groups, and there were no correlations between
the changes in the total SWNS score and the BACS
items. Thus, the subjective well-being of patients with
schizophrenia did not differ between RLAI and PP, des-
pite the higher improvement in some cognitive domains
observed in the PP group. However, a correlation be-
tween emotional regulation (a SWNS subscale) and at-
tention/processing speed improvement during treatment
was found. Gross et al. assumed a model of emotion
regulation that includes five phases and hypothesized
that attention plays an important role in this process
[54]. The event-related potentials measured by an elec-
troencephalographic study and a functional magnetic
resonance imaging study demonstrated a relationship
between attention and emotional regulation [55, 56]. In
addition, numerous reports have examined the dysfunc-
tional interactions between attention and unpleasant
stimuli, which are particularly interesting in regard to
schizophrenia [57]. However, the current evidence ap-
pears still insufficient to state that improvements in
attention during the pharmacological treatment of
schizophrenia can result in improvements of emo-
tional regulation [57]. In addition, the SWNS sub-
scales may be greatly affected by the total score and
they may have low reliability [58]. Thus, further stud-
ies focused on this issue are needed.
This study has several limitations. First, the small sam-
ple size increases the risk of false negative findings. The
lack of multiple-testing correction (e.g. Bonferroni cor-
rection) may also result in type I errors, but given the
pilot nature of the present study, the results should be
considered preliminary. Therefore, replication studies
are needed, possibly with larger samples and through a
randomized, double blind design. Second, the open-label
design might have affected the results, since the expecta-
tions of patients or raters might have affected the assess-
ments. However, the similar effects of the two drugs on
symptomatology scores do not support this bias and the
randomized design represents a point of strength. Third,
we did not consider the drug blood level at the time of
the cognitive assessment or of the other assessments.
The drug blood level may have affected these evaluations
[31], despite drug level fluctuations for LAIs are consid-
erably smaller than for oral antipsychotics [59]. Finally,
we did not strictly limit the use of anticholinergic agents,
which may have an impact on cognitive function. How-
ever, only one patient in the RLAI group used anti-
cholinergic agents, with probably no impact on the
present results. Future studies should fix the timing of
cognitive assessments and strictly control the use of con-
comitant medications.
Conclusions
To the best of our knowledge, this is the first study to
compare the influence of RLAI and PP on cognitive func-
tional domains and well-being. Compared to continue
treatment with RLAI, switching from RLAL to PP therapy
may have more favorable effects on attention and process-
ing speed (as assessed using the BACS scale), which are
important elements in cognitive function, although there
were neither differences in symptom improvement ac-
cording to the PANSS, nor in the frequency of extrapyr-
amidal side effects. The higher improvement in attention
and processing speed found in the PP group was associ-
ated with higher improvement in emotional regulation
(accordingly to the SWNS). However, these results are
preliminary and independent replication in larger samples
is required before any definitive statement.
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